NCT07450820Completed
OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD
A Multinational, Observational, Retrospective, Secondary Data Study Analyzing Dapagliflozin Effectiveness in Routine Clinical Practice Among Patients With Chronic Kidney Disease. Local Adaptation for Spain. Part 2
Source: ClinicalTrials.gov · Last updated 27 May 2026
Brief summary (registry, in English)
This is a retrospective, observational study, using secondary data captured in electronic health records (EHRs). The study is a part of the OPTIMISE-CKD program to assess the current CKD treatment landscape, Dapagliflozin utilisation and characterization of incident CKD patient and the burden of disease within an observation period of 39 months (August 2020-November 2024) in two cohorts (preand post-reimbursement of Dapagliflozin for CKD)
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 12894 (actual)
- First submitted
- 4 Feb 2026
- Start date
- 18 Feb 2026
- Primary completion date
- 6 May 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Chronic kidney disease
- NCT number
- NCT07450820
What you commit to
- Study type: Observational
- Participants enrolled: 12894
- From 18 Feb 2026 to the primary completion date, 6 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of gestational diabetes mellitus on or before index date
Other
- T1DM on or before index date.
Who the study is looking for
- Meets CKD definition criteria: having at least two eGFR measures ≤60 ml/min/1.73m2 measured ≥90 to 730 days apart and/or UACR ≥ 30 mg/g, and/or at least one measurement indicative of proteinuria (or with proteinuria ERA-ICD code) or CKD code.
- Age ≥18 years.
- 12 months continuous enrolment in the data base prior to index
- 12 months continuous enrolment in the data base after index date.
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.